What's new

What's new

Annual activity report 2024

Annual activity report 2024

27 June 2025

Human medicines European public assessment report (EPAR): Xelevia, sitagliptin, Date of authorisation: 21/03/2007, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Xelevia, sitagliptin, Date of authorisation: 21/03/2007, Revision: 41, Status: Authorised

27 June 2025

Human medicines European public assessment report (EPAR): Tesavel, sitagliptin, Date of authorisation: 10/01/2008, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Tesavel, sitagliptin, Date of authorisation: 10/01/2008, Revision: 28, Status: Authorised

27 June 2025

Human medicines European public assessment report (EPAR): Ristaben, sitagliptin, Date of authorisation: 15/03/2010, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Ristaben, sitagliptin, Date of authorisation: 15/03/2010, Revision: 29, Status: Authorised

27 June 2025

Human medicines European public assessment report (EPAR): Avamys, fluticasone furoate, Date of authorisation: 11/01/2008, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Avamys, fluticasone furoate, Date of authorisation: 11/01/2008, Revision: 25, Status: Authorised

27 June 2025

Withdrawn application: Lutathera, 09/05/2025

Withdrawn application: Lutathera, 09/05/2025

27 June 2025

Human medicines European public assessment report (EPAR): Eylea, aflibercept, Date of authorisation: 21/11/2012, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Eylea, aflibercept, Date of authorisation: 21/11/2012, Revision: 37, Status: Authorised

27 June 2025

Human medicines European public assessment report (EPAR): Tresiba, insulin degludec, Date of authorisation: 20/01/2013, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Tresiba, insulin degludec, Date of authorisation: 20/01/2013, Revision: 19, Status: Authorised

27 June 2025

Human medicines European public assessment report (EPAR): Saxenda, liraglutide, Date of authorisation: 23/03/2015, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Saxenda, liraglutide, Date of authorisation: 23/03/2015, Revision: 18, Status: Authorised

27 June 2025

Human medicines European public assessment report (EPAR): Zoonotic Influenza Vaccine Seqirus, zoonotic influenza vaccine (H5N8) (surface antigen, inactivated, adjuvanted), Date of authorisation: 09/10/2023, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Zoonotic Influenza Vaccine Seqirus, zoonotic influenza vaccine (H5N8) (surface antigen, inactivated, adjuvanted), Date of authorisation: 09/10/2023, Revision: 3, Status: Authorised

27 June 2025